Coagulation Factor III

Coagulation Factor III Overview

English NameTissue factorApproved Drugs1
Drugs in Clinical Trials7Target SynonymCoagulation Factor III (Thromboplastin, Tissue Factor),Thromboplastin,Coagulation Factor III, Tissue Factor,TFA,F3,TF,CD142 Antigen,CD142,Coagulation Factor III,Tissue Factor
Highest Development StageApproved
English NameTissue factor
Target SynonymCoagulation Factor III (Thromboplastin, Tissue Factor),Thromboplastin,Coagulation Factor III, Tissue Factor,TFA,F3,TF,CD142 Antigen,CD142,Coagulation Factor III,Tissue Factor
Approved Drugs1
Drugs in Clinical Trials7
Highest Development StageApproved

Coagulation Factor III Background

Full-length tissue factor (TF) is a transmembrane receptor and cofactor for factor (F)VII/FVIIa. In addition to full-length TF, an alternative spliced (as) form of TF can be generated that lacks the transmembrane domain and is released fromcells. In contrast to TF, asTF has low procoagulant activity because it lacks the transmembrane domain. Tissue factor is expressed by cells around blood vessels, such as adventitial fibroblasts, and body surfaces, such as epithelial cells, and plays a critical role in hemostasis. TF also contributes to various forms of thrombosis. Many cancers, particularly adenocarcinomas, express high levels of TF. A high level of tumor TF expression is associated with poor prognosis in many types of cancers, including breast, prostate, colorectal, and pancreatic cancer.

Coagulation Factor III Synonyms

Coagulation Factor III,Tissue Factor,TF,F3,CD142

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
AnpocoginAB-201Phase 3 ClinicalDendreon Uk LtdCoronavirus Disease 2019 (COVID-19)
Details
XNW-28012XNW-28012; XNW28012Phase 3 ClinicalShanghai Cigna Biotech Pharmaceutical Co LtdOvarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Uterine Cervical Neoplasms
Details
MRG-004AMRG004APhase 3 ClinicalShanghai Miracogen IncPancreatic Neoplasms; Solid tumours
Details
XB-002XB-002; ICON-2Phase 1 ClinicalIconic Therapeutics IncBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urogenital Neoplasms; Uterine Cervical Neoplasms
Details
XB-371XB-371; XB371Phase 1 ClinicalCatalent Inc, Exelixis IncNeoplasms; Solid tumours
Details
STRO-004STRO-004Phase 1 ClinicalSutro Biopharma IncCarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms
Details
AMT-754ADCE-T02; AMT-754Phase 1 ClinicalMultitude Therapeutics IncSolid tumours
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Tisotumab vedotinTF-011-MMAEApprovedGenmab A/SHuMax-TF, TIVDAKUnited StatesUterine Cervical NeoplasmsSeagen Inc2021-09-20Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland